Status:

UNKNOWN

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

Lead Sponsor:

Oregon Health and Science University

Collaborating Sponsors:

Aarhus University Hospital

Conditions:

Adults Growth Hormone Deficiency.

Eligibility:

All Genders

21-55 years

Phase:

NA

Brief Summary

Hypothesis: Pegvisomant combined with the glucagon stimulation test (GST) can improve the accuracy of this test when used to diagnose adult GH and cortisol (steroid hormone)insufficiency. Study aims...

Detailed Description

Background: The diagnosis of GH deficiency in adults is established by provocative testing of GH secretion. The insulin tolerance test (ITT) is widely regarded as the gold standard test for diagnosing...

Eligibility Criteria

Inclusion

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study.
  • Age 21 to 55 years
  • Body weight 60 to 120 kg inclusive
  • Stable weight and diet for at least 3 months prior to study entry

Exclusion

  • Poor IV access
  • Known hypersensitivity to glucagon
  • Inability or unwillingness to comply with study procedures
  • Clinically significant cardiovascular or cerebrovascular disease
  • Current active malignancy other than non-melanoma skin cancer
  • Active acromegaly or Cushing's disease
  • Pheochromocytoma
  • Pregnancy
  • Renal failure (serum creatinine \> 2 mg/dl)
  • Severe acute illness
  • Uncontrolled hypertension (BP \> 160/100 mmHg)
  • Emotional/social instability likely to prejudice study completion
  • Recurrent or severe unexplained hypoglycemia
  • Known or suspected drug/alcohol abuse
  • Patients with history of coronary artery disease, cerebrovascular disease, congestive heart failure, arrhythmias and seizure disorder that would be excluded from the ITT arm regardless of age
  • Participation in another simultaneous medical investigation or trial

Key Trial Info

Start Date :

March 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2013

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT01804413

Start Date

March 1 2011

End Date

December 1 2013

Last Update

October 24 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Oregon Health & Science University

Portland, Oregon, United States, 97239